Targeted Delivery of the HLA-B*27-Binding Peptide into the Endoplasmic Reticulum Suppresses the IL-23/IL-17 Axis of Immune Cells in Spondylarthritis

Hui-Chun Yu,1 Kuang-Yung Huang,2,3,4 Ming-Chi Lu,1,2,3 Hsien-Lu Huang,5 Su-Qin Liu,2 Ning-Sheng Lai,2,3 and Hsien-Bin Huang4

1Department of Medical Research, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
2Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Buddhist Dalin Tzu Chi Hospital, Chiayi, Taiwan
3School of Medicine, Tzu Chi University, Hualien City, Taiwan
4Department of Life Science and Institute of Molecular Biology, National Chung Cheng University, Chiayi, Taiwan
5Department of Nutrition and Health Science, Fooyin University, Kaohsiung City, Taiwan

Correspondence should be addressed to Ning-Sheng Lai; Q12015@tzuchi.com.tw and Hsien-Bin Huang; biohhb@ccu.edu.tw

Received 13 June 2017; Revised 19 September 2017; Accepted 23 October 2017; Published 31 December 2017

1. Introduction

Ankylosing spondylitis (AS) is an inflammatory disease that is characterized by inflammatory back pain and asymmetric peripheral oligoarthritis [1–4]. The development of AS is strongly linked with the expression of human leukocyte antigen-B27 (HLA-B*27). HLA-B*27 heavy chain (B27-HC) has an intrinsic propensity to fold slowly, leading to the accumulation of the misfolded B27-HC in the endoplasmic reticulum (ER) and formation of the HLA-B*27 HC homodimer, (B27-HC)2, by a disulfide linkage at Cys-67. (B27-HC)2 displayed on the cell surface can act as a ligand of the killer-cell Ig-like receptor (KIR3DL2). (B27-HC)2 binds to KIR3DL2 of NK and Th17 cells and activates both cells, resulting in the activation of the IL-23/IL-17 axis to launch the inflammatory reaction in AS patients. However, activation of the IL-23/IL-17 axis originally derived from the HLA-B*27 misfolding in the ER needs to be characterized. In this study, we delivered two HLA-B*27-binding peptides, KRGILTLKY and SRYWAIRTR, into the ER by using a tat-derived peptide (GRKKRRQRRR)-His6-ubiquitin (THU) vehicle. Both peptides are derived from the human actin and nucleoprotein of influenza virus, respectively. Our results demonstrated that targeted delivery of both HLA-B*27-binding peptides into the ER can promote the HLA-B*27 folding, decrease the levels of (B27-HC)2, and suppress the activation of the IL-23/IL-17 axis in response to lipopolysaccharide. Our findings can provide a new therapeutic strategy in AS.
present on the membranes of natural killer (NK) cells and T-helper 17 (Th17) cells. Recent studies have demonstrated that (B27-HC)₂ can interact with the KIR3DL2 receptor and promote the survival and growth of both NK cells and Th17 cells [13, 14]. Activation of NK cells and Th17 cells by (B27-HC)₂ may make one of the contributions to the pathogenesis of AS.

In addition, the misfolded B27-HC accumulated in the lumen of the ER can associate with Grp78/Bip that functions as a chaperone protein [1, 15, 16]. Under normal conditions without remarkable accumulation of misfolded and unfolded proteins in the lumen of the ER, Grp78/Bip binds to three sensors, ATF6, IRE1, and PERK, of unfolded protein response (UPR) on the membrane of the ER and blocks their functions [17, 18]. The buildup of misfolded B27-HC in the ER provides the new target for Grp78/Bip binding. Consequently, Grp78/Bip discharges from its initial complexes, allowing the sensor proteins to induce UPR [17]. Indeed, the misfolded B27-HC overexpressed in HMy2.C1R cells was observed to associate with Grp78/Bip in the coimmunoprecipitation assay [15, 16]. In the HLA-B*27 transgenic rat, the ER stress induced by the overexpressed HLA-B*27 activates the UPR, upregulates the expression of proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), IL-1, IL-6, and IL-23 [19–21]. Bone marrow-derived macrophages releasing IL-23 to activate Th17 cells were observed when UPR was induced by the accumulation of misfolded B27-HC in transgenic rats.

Recent studies have indicated that the HLA-B*27-binding peptide in the ER can promote HLA-B*27 folding and suppress the formation of (B27-HC)₂ [22, 23]. In our previous studies, we have designed a novel His₆-ubiquitin-tagged Tat-derived peptide (THU) vehicle to deliver the HLA-B*27-binding peptides, RRFKEGGRGGKY and RRYLENGKETL, from the extracellular space into the ER [16]. Both delivered peptides are derived from the DNA primase of Chlamydia trachomatis and human B27-HC, respectively [24, 25]. The primary sequence of THU, from the N-terminus to the C-terminus, contains a Tat-derived peptide, a His₆ tag, and ubiquitin. The cargo peptide is immediately linked to the C-terminus of ubiquitin. The human immunodeficiency virus Tat-derived peptide, GRKKRRQRRR, is a small basic peptide that can efficiently translocate various types of cargo, including oligopeptides, across membranes [26, 27]. The THU-HLA-B*27-binding peptide fusion protein was rapidly translocated into the cytosol, where the HLA-B*27-binding peptide was discharged from THU by a specific cleavage reaction carried out by cytosolic ubiquitin C-terminal hydrolases (UCHs). The released peptide was then translocated into the lumen of the ER by the transporter associated with antigen processing (TAP) [28, 29]. In the ER, the HLA-B*27-binding peptide can promote the folding of B27-HC and suppress the formation of (B27-HC)₂. The levels of (B27-HC)₂ were decreased, and the concentrations of the assembled HLA-B*27 HC/β₂m/peptide complex on the cell membrane were increased. However, it remained unknown whether promotion of HLA-B*27 folding in the ER can suppress the IL-23/IL-17 axis of the immune cells in AS. In this study, we delivered two new HLA-B*27-binding peptides, KRGILTLKY and SRY-WAIRTR, into the ER by the THU vehicle. Our results demonstrated that targeted delivery of the HLA-B*27-binding peptide into the ER can promote the HLA-B*27 folding and suppress the IL-17A or IL-17A/IL-23 expressions of PBMCs isolated from AS patients in response to lipopolysaccharide (LPS), indicating the strong linkage between HLA-B*27 misfolding in the ER and activation of the IL-23/IL-17 axis in AS.

2. Materials and Methods

Acrylamide, nickel chloride, dithiothreitol (DTT), Tris, Luria-Bertani (LB) broth, ampicillin, EDTA, imidazole, isopropyl β-D-1-thiogalactopyranoside (IPTG), phenylmethylsulfonyl fluoride (PMSF), lipopolysaccharide (LPS), MOPS, puromycin, benzamidine, sodium dodecyl sulfate, sodium azide, sodium chloride, TEMED, ammonium persulfate, glycine, and hygromycin B were obtained from Sigma-Aldrich (St. Louis, MO, USA). Chelating Sepharose and SP Sepharose were purchased from GE Healthcare (Uppsala, Sweden). Preparations of tat-derived peptide (GRKKRRQRRR)-His₆-ubiquitin (THU) and THU-RRFKKEGGRGGKY (THUC) followed the methods [16].

2.1. Protein Purification. The cDNAs encoding THU-KRGILTLKY (THUA), THU-SRY-WAIRTR (THUNP), His₆-ubiquitin-KRGILTLKY (HUA), and His₆-ubiquitin-SRY-WAIRTR (HUNP) were constructed by a two-step polymerase chain reaction (PCR). The primers used for PCR amplification are listed in Supplementary Figure S1. The resulting product from the first PCR was used as a template for the second PCR. The resulting product of the second PCR was cloned into pET28a at the Nhel/Xhol sites of the plasmid. E. coli BL21 (DE3) cells transformed with the recombinant vector encoding THUA, THUNP, HUA, or HUNP were grown in one liter of LB broth with 0.5 g/liter kanamycin sulfate at 37°C with shaking at 250 rpm. When the absorbance at 600 nm was between 0.6 and 1.0, 0.38 g of IPTG was added for a final concentration of 1 mM to induce protein expression. Bacteria were harvested by centrifugation after three-hour induction. The pellet cells were resuspended in 30 ml of 20 mM Tris-HCl buffer (pH 7.9), containing 0.5 M NaCl, 0.2 mM PMSF, 0.02% sodium azide, and 4 mM benzamidine, and lysed by French press. The insoluble components were removed by centrifugation at 20,000 g for 20 min. The supernatant was loaded onto a Ni²⁺ Sepharose column (2.5 × 10 cm). After washing with one volume of the same buffer, bound proteins were eluted with a linear imidazole gradient from 5 mM (500 ml) to 1.0 M imidazole (500 ml) in the same buffer. The fractions containing the expressed protein were pooled, dialyzed against the deionized water (two liters) with five changes during 36 hours to remove the excess reagents, and lyophilized to powder. The lyophilized protein was then dissolved with 20 ml of 20 mM MOPS (pH 7.0) and 0.2 mM EDTA. All components were resolved by SP Sepharose chromatography (2.5 × 20 cm) with a linear gradient from 0 (500 ml) to 2 M NaCl (500 ml). The fractions
containing the target protein were pooled, dialyzed against the deionized water, and lyophilized.

2.2. Ethics Statement. Patients defined according to the modified New York criteria [30] were recruited into the study between January 2014 and December 2014 in a regional teaching hospital in Southern Taiwan. The experimental procedures for the separation of human PBMCs from AS patients have been evaluated and approved by the Institutional Review Board (IRB) of Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan (number B10302005). Written informed consent was obtained from all study patients. Human PBMCs from the AS patients were prepared following the methods as previously described [31].

2.3. Western Blotting Analysis. HMY2.C1R cells (ATCC, Manassas, VA) belong to the B-lymphoblast cells that deficiently express the HLA-A* or HLA-B* genes [32]. Both C1R-B* 27:04 cells and TAP1-knockdown C1R-B* 27:04 cells were derived from HM2.C1R cells that stably overexpress HLA-B* 27:04 heavy chain (B2704-HC), a subtype of B27–HC [16]. C1R-B* 27:04 cells (3 × 10⁶ cells/well) were grown on 24-well plates and maintained in 1 ml of Iscove’s modified Dulbecco’s medium (IMDM) (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS) (Invitrogen) and 200 μg/ml hygromycin B. C1R-B* 27:04 cells (3 × 10⁶ cells/well) with TAPI knockdown were maintained in the same medium with 0.4 μg/ml puromycin. Cells were treated with 20 μg of THUA, THU, HUA, THUNP, or HUNP and harvested at the indicated time. Membrane proteins were extracted using a ProteoExtract Native Membrane Protein Extraction Kit (Calbiochem, Darmstadt, Germany) and following the manufacturer’s instruction. Fresh iodoacetamide (10 mM) was included in all buffers to block disulfide bridge formation during membrane protein extraction. Aliquots of extracted membrane proteins in the supernatant were separated by nonreducing SDS-PAGE (10%). Membrane proteins were transferred to polyvinyl difluoride membranes (GE Healthcare); immunoblotted with BH2, an anti-misfolded HLA-B* 27 monoclonal antibody [16]; and analyzed by horseradish peroxidase-(HRP-) conjugated goat anti-mouse IgG (Santa Cruz Biotechnology, Dallas, TX).

2.4. Flow Cytometry. All assays followed the methods as described [16]. C1R-B* 27:04 cells (2 × 10⁶ cells per well) or TAP1-knockdown C1R-B* 27:04 cells (2 × 10⁶ cells per well) were grown in 1 ml IMDM with 10% FBS, 200 μg/ml hygromycin B, and 0.4 μg/ml puromycin. Cells were treated with 10 μM THUA, 10 μM THU, 10 μM THUNP, or 10 μM HUNP overnight, followed by washing with PBS three times and staining with a W6/32 antibody (Abcam, Cambridge, MA; 1:500 dilution) in the dark for 30 min. After washing with PBS three times, the stained cells were incubated with goat FITC-conjugated anti-mouse IgG (Millipore, Temecula, CA; 1:500 dilution) in the dark for 30 min, washed with PBS three times, and analyzed by flow cytometry.

2.5. Quantitative Real-Time Reverse Transcriptase PCR. PBMCs (3 × 10⁶ cells) isolated from AS patients were maintained in RPMI1640 medium and treated with 200 ng LPS plus 20 μg THUC, THU, or THUNP at 37°C with 5% CO₂ for 24 h. The total RNAs of treated PBMCs were isolated by using the QIAamp RNA Blood Mini Kit (QIAGEN GmbH, Germany). IFN-γ, TNF-α, IL-6, IL-17A, or IL-23 mRNA was amplified by real-time PCR using a One Step SYBR Ex Taq qRT-PCR kit (TaKaRa, Shiga, Japan).

2.6. Statistical Analysis. Data are displayed as means ± SD. P values were obtained by the Mann–Whitney U test. P values less than 0.05 were considered statistically significant.

3. Results

3.1. Protein Purification. The recombinant THU-KRGILTLKY (THUA), THU-SRYWAIRTR (THUNP), His₆-ubiquitin-KRGILTLKY (HUA), or His₆-ubiquitin-SRYWAIRTR (HUNP) was individually overexpressed in E. coli BL21 (ED3) and purified by a two-step chromatography. Both KRGILTLKY and SRYWAIRTR peptides are derived from the human actin and nucleoprotein of influenza virus, respectively [33]. After rupture of cells by French press, the crude extract was purified by Ni²⁺ Sepharose chromatography and SP Sepharose chromatography. The homogeneity of each purified protein was analyzed by SDS-PAGE (Figure 1).

3.2. Targeted Delivery of HLA-B* 27-Binding Peptides into the ER Promotes HLA-B* 27 Folding. We used the THU vehicle to deliver two HLA-B* 27-binding peptides, KRGILTLKY and SRYWAIRTR, to the ER of C1R-B* 27:04. We firstly verified whether treatment with THUA lowered the production of
(B27-HC)$_2$ in C1R-B$^\ast$ 27:04 cells. BH2, a monoclonal antibody that can recognize (B27-HC)$_2$, was used in our early study [16, 34]. Figures 2(a) and 2(b) show that the levels of (B27-HC)$_2$ are decreased in THUA-treated cells, whereas neither THU nor HUA treatment changes the levels of (B27-HC)$_2$. Treatment of C1R-B$^\ast$ 27:04 with THUA, HUA, THUNP, HUNP, or THU had no effect on the expression levels of B27-HC (Figure 2(c)). Thus, it is clear that THUA enters the cells via the Tat peptide. The cargo peptide is liberated from THUA in the cytosol via cleavage by endogenous ubiquitin C-terminal hydrolases and then is transported into the lumen of the ER by TAP to promote B27-HC folding. A similar consequence was obtained when C1R-B$^\ast$ 27:04 cells were treated with THUNP. The formation of (B27-HC)$_2$ in C1R-B$^\ast$ 27:04 cells was significantly suppressed by the treatment with THUNP (Figures 2(d) and 2(e)). Neither HUNP nor THU treatment was capable of suppressing the production of (B27-HC)$_2$ (Figures 2(d) and 2(e)). TAP, a heterodimeric protein consisting of TAP1 and TAP2 subunits, is located on the ER membrane, belonging to one of the ATP-binding cassette (ABC) transporter members [28]. The cytosolic peptides are translocated by TAP into the ER, where they assemble with MHC class I molecules for shipping to the cell surface. We demonstrated that knockdown of a TAP1 subunit can disrupt the THUNP-promoted reduction of (B27-HC)$_2$ formation (Figures 2(f) and 2(g)). However, knockdown of TAP1 did not affect the expression of B27-HC in C1R-B$^\ast$ 27:04 cells (Figure 2(c)), suggesting that suppression of (B27-HC)$_2$ formation by THUNP treatment was due to the impairment of TAP activity.

### 3.3. The Delivered Peptides Can Be Displayed on the Cell Surface

Assuming that the actin peptide or NP peptide has been targeted to the ER lumen of C1R-B$^\ast$ 27:04 by the THU vehicle, it will enhance B27-HC folding and assemble into the B27-HC/$\beta$$_m$ heterotrimERIC complex. Thus, the amount of the assembled B27-HC/$\beta$$_m$/peptide heterotrimERIC complex will be increased and then will be transported to the cell surface. Two populations of C1R-B$^\ast$ 27:04 cells were observed by flow cytometric analysis (Figures 3(a) and 3(c)). Cells in the small population account for around 22% of the total C1R-B$^\ast$ 27:04 cells but display the low levels of HLA-B$^\ast$ 27:04 on the cell surface, as judged by the W6/32 staining. This may suggest that the expression of the B27-HC is low in this population. Another population contains most of the C1R-B$^\ast$ 27:04 cells. The cells in this group display the high levels of the HLA-B$^\ast$ 27:04 on the cell surface. As a result, the levels of the assembled B27-HC/$\beta$$_m$/peptide heterotrimERIC complex on the cell membrane will be increased. Thus, we analyzed whether the ER-targeted actin or NP peptide has been transported to the cell plasma membrane by the B27-HC/$\beta$$_m$ complex of C1R-B$^\ast$ 27:04. If the folded B27-HC/$\beta$$_m$/peptide heterotrimERIC complex is present on the plasma membrane, it will be identified by W6/32, a monoclonal antibody that recognizes the folded MHC class I molecules [35]. After C1R-B$^\ast$ 27:04 cells were treated with THUA or THUNP, the population of W6/32-reactive cells was clearly increased (Figures 3(a)–3(d)), suggesting that the actin peptide or NP peptide has been presented on the cell surface by the B27-HC/$\beta$$_m$ complex. However, an increased W6/32-reactive cell population was not observed when C1R-B$^\ast$ 27:04 cells were treated with THU, HUA, or HUNP (Figures 3(a)–3(d)). Moreover, impairment of TAP function by knockdown of TAP1 diminished the translocation of the antigenic peptide into the ER, resulting in lowering the assembly of the B27-HC/$\beta$$_m$ complex with the antigenic peptide and reducing the peptide presentation on the cell membrane. Apparently, the cargo peptide presented on the cell surface of TAP-knockdown cells was suppressed even though they were treated with THUA or THUNP (Figures 3(a)–3(d)).

### 3.4. Targeted Delivery of HLA-B$^\ast$ 27-Binding Peptides into the ER Suppresses the IL-23/IL-17 Axis of PBMCs Isolated from AS Patients in Response to LPS

Several lines of evidence have indicated that the IL-23/Th17 axis is highly involved in AS pathogenesis [21, 36–38]. Then, we asked whether targeted delivery of the HLA-B$^\ast$ 27-binding peptide to the ER can suppress the IL-23/IL-17 expression of PBMCs isolated from AS patients in response to LPS. Cytokine expression in the HLA-B$^\ast$ 27-expressing PBMCs was stimulated by LPS in the absence of THU, THUC, or THUNP (Figure 4(a)). Figure 4(b) shows that targeted delivery of the HLA-B$^\ast$ 27-binding peptide to the ER by THU can suppress the expression of IL-17A by HLA-B$^\ast$ 27-expressing PBMCs. We also observed that treatment with THUNP can reduce the IL-23 and TNF-α expressions of PBMCs (Figure 4(b)). Targeted delivery of the HLA-B$^\ast$ 27-binding peptide into the ER failed to affect the expression of IL-6 (Figure 4(b)) and IFN-γ mRNAs (Figure 4(b)).

### 4. Discussion

An overwhelming expression of B27-HC has been proved to spontaneously develop the AS-like disease in the transgenic rat [19–21]. In the HLA-B$^\ast$ 27 transgenic rat model, accumulation of the misfolded B27-HC in the ER can trigger UPR. The levels of mRNAs for UPR markers, including Grp78, CHOP, and XBP-1 transcription factor, were significantly increased in bone marrow-derived macrophages, where accumulation of misfolded heavy chain induced by HLA-B$^\ast$ 27 upregulation highly correlated with the magnitude of the UPR. IL-23 production in bone marrow-derived macrophages suffering a UPR triggered by thapsigargin or by HLA-B$^\ast$ 27 misfolding was synergistically stimulated by LPS. IL-23 is a key cytokine to induce the differentiation of naïve CD4+ T-cells into Th17 cells that produce proinflammatory cytokines, including IL-17 [39]. Stimulation of the IL-23/IL-17 axis provides the strong linkage between HLA-B$^\ast$ 27 misfolding and UPR in transgenic rats. However, the linkage between activation of UPR and production of proinflammatory cytokines in AS pathogenesis remained unclear [38]. Macrophages derived from AS patients in response to LPS failed to stimulate the UPR but significantly upregulated IL-23 production, supporting that the IL-23/IL-17 axis is highly involved in the AS pathogenesis and is a therapeutic target [38].

Mediators of Inflammation
Figure 2: Continued.
(B27-HC)_2 is a key molecule in AS pathogenesis. Most of AS patients display (B27-HC)_2 on their PBMCs [40]. The mean grades of sacroiliitis and the lumbar spine bath ankylosing spondylitis radiology index scores are higher in AS patients with (B27-HC)_2 on their PBMCs [40]. (B27-HC)_2 is one of the ligands for KIR3DL2 that is present on the cell surface of NK and Th17 cells. (B27-HC)_2 is capable of stimulating Th17 cells for IL-17 production and promoting the proinflammatory reaction. Although KIR3DL2+ cells consist of the 15% of CD4 T-cells in PBMCs, this subgroup accounts for the major numbers of Th17 in AS patients [13, 14]. A monoclonal antibody, HD6, screened from a human phage display library can specifically recognize the recombinant (B27-HC)_2 in the binding assays [41]. HD6 can block the binding of (B27-HC)_2 to KIR3DL2 and inhibit the survival and growth of KIR3DL2+ NK cells. HD6 suppresses the IL-17 production of PBMCs isolated from AS patients. In this study, we demonstrated that targeted delivery of the HLA-B*27-binding peptide into the ER can suppress the IL-23/IL-17 axis of PBMCs isolated from AS patients (Figures 4(a) and 4(b)). Suppression of IL-17 mRNA expression in response to LPS might be due to the reduction of (B27-HC)_2 production after treatment of PBMCs with THUC, THUA, or THUNP. Thus, stimulation of KIR3DL2+ NK and Th17 cells by (B27-HC)_2 is decreased, diminishing the production of IL-17.

AS is a chronic inflammatory disease of the axial skeleton. The regions in joints of the spine and in the sacroiliac joint of the pelvis are mainly affected in AS patients. In serious cases, patients will gradually develop ankylosis and syndesmophytes over time [4]. Nonsteroidal anti-inflammatory drugs (NSAIDs) are regularly employed for AS treatment; TNF-α blockers are used in most NSAID-resistant AS patients. However, although anti-TNF-α therapy can eliminate much of the inflammation, development of syndesmophyte formation cannot be terminated [4, 42]. Side effects, such as an increased risk of fungal infections and of tuberculosis for the patients with latent _Mycobacterium tuberculosis_ infections, are escalated after anti-TNF-α therapy [43], or some patients poorly respond to this therapy. In addition, the recent report has indicated that the IL-23/IL-17 axis is not affected by anti-TNF-α therapy in AS patients [44]. Recently, the therapeutic target of AS has been focused on the IL-23/IL-17 axis. Several potential monoclonal antibodies targeting IL-23/IL-17 pathways have been carried out in a clinical trial for AS treatment [45, 46].

5. Conclusion

Activation of the IL-23/IL-17 axis in AS pathogenesis is originally derived from the HLA-B*27 misfolding in the ER. Our results have demonstrated that targeted delivery of the HLA-B*27-binding peptide to the ER by using the THU vehicle can promote the HLA-B*27 folding, decrease the (B27-HC)_2 production, and suppress the activation of the IL-23/IL-17 axis. Our results confirmed the strong linkage between the HLA-B*27 misfolding and activation of the IL-23/IL-17 axis in AS pathogenesis. Our construct
Figure 3: Treatment with either THUA or THUNP increases the antigenic peptide targeted to the cell surface of C1R-B*27:04. (a) Treatment with THUA, but not with THU or HUA, increases the HLA-B*27:04 HC/β2m/KRGILTLKY complex presented at the cell surface of C1R-B*27:04, as detected by flow cytometry. Knockdown of TAP1 ruins the antigenic peptide, KRGILTLKY, presented on the cell surface. (b) Mean channel fluorescence measured in (a) was averaged from three independent experiments (mean ± SD, n = 3). Values of mean channel fluorescence measured from the large population of C1R-B*27:04 cells that display the high levels of HLA-B*27:04 on the cell surface were increased when cells were treated with THUA. (c) Treatment with THUNP, but not with THU or HUNP, increases the HLA-B*27:04 HC/β2m/SRYWAIRTR complex presented at the cell surface, as detected by flow cytometry. TAP1 knockdown impairs the antigenic peptide, SRYWAIRTR, presented on the cell surface. (d) Mean channel fluorescence measured in (c) is increased when C1R-B*27:04 cells were treated with THUNP. Values (mean ± SD, n = 3) measured from the high population of cells that display the high levels of HLA-B*27:04 on the cell surface are averaged from three independent experiments. Statistical significance was obtained by the Mann–Whitney U test.
for peptide delivery has a potential application in the development of the peptide therapy for AS.

**Conflicts of Interest**

The authors declare no competing financial interests.

**Authors’ Contributions**

Hui-Chun Yu and Kuang-Yung Huang contributed equally to this work.

**Acknowledgments**

This work was supported by grants from the Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (DTCRD 105-E-16, DTCRD 104(2)-I-01), and Tzu Chi Medical Mission Project 105-01-03, Buddhist Tzu Chi Medical Foundation, and from the National Science Council, Taiwan ROC (NSC 102-2320-B-194-002).

**Supplementary Materials**

Figure S1: Sequences of primers used for PCR.

(Supplementary Materials)
References

[1] R. A. Colbert, M. L. DeLay, E. I. Klenk, and G. Layh-Schmitt, "From HLA-B27 to spondyloarthritis: a journey through the ER," *Immunological Reviews*, vol. 233, no. 1, pp. 181–202, 2010.

[2] L. Melis and D. Elewaut, "Progress in spondylarthitis. Immunopathogenesis of spondyloarthitis: which cells drive disease?", *Arthritis Research & Therapy*, vol. 11, no. 3, p. 233, 2009.

[3] J. A. Smith, E. Marker-Hermann, and R. A. Colbert, "Pathogenesis of ankylosing spondylitis: current concepts," *Best Practice & Research. Clinical Rheumatology*, vol. 20, no. 3, pp. 571–591, 2006.

[4] L. S. Tam, J. Gu, and D. Yu, "Pathogenesis of ankylosing spondylitis," *Nature Reviews Rheumatology*, vol. 6, no. 7, pp. 399–405, 2010.

[5] M. F. Caffrey and D. C. James, "Human lymphocyte antigen association in ankylosing spondylitis," *Nature*, vol. 242, no. 5393, p. 121, 1973.

[6] D. A. Brewerton, F. D. Hart, A. Nicholls, M. Caffrey, D. C. James, and R. D. Sturrock, "Ankylosing spondylitis and HLA-B27," *Lancet*, vol. 1, no. 7809, pp. 904–907, 1973.

[7] D. R. Madden, "The three-dimensional structure of peptide–MHC complexes," *Annual Review of Immunology*, vol. 13, no. 1, pp. 587–622, 1995.

[8] R. L. Allen, A. A. O’Callaghan, A. J. McMichael, and P. Bowness, "Cutting edge: HLA-B27 can form a novel β₂-microglobulin-free heavy chain homodimer structure," *Journal of Immunology*, vol. 162, no. 9, pp. 5045–5048, 1999.

[9] S. Kollnberger, L. Bird, M. Y. Sun et al., "Cell-surface expression and immune receptor recognition of HLA-B27 homodimers," *Arthritis and Rheumatism*, vol. 46, no. 11, pp. 2972–2982, 2002.

[10] N. S. Dangoria, M. L. DeLay, D. J. Kingsbury et al., "HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum," *Journal of Biological Chemistry*, vol. 277, no. 26, pp. 23459–23468, 2002.

[11] S. D. Kollnberger, L. A. Bird, M. Roddis et al., "HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthrits and are ligands for paired Ig-like receptors," *Journal of Immunology*, vol. 173, no. 3, pp. 1699–1710, 2004.

[12] A. T. Chan, S. D. Kollnberger, L. R. Wedderburn, and P. Bowness, "Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL1 in spondyloarthrits," *Arthritis and Rheumatism*, vol. 52, no. 11, pp. 3586–3595, 2005.

[13] P. Bowness, A. Ridley, J. Shaw et al., "Th17 cells expressing KIR3DL2 and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis," *Journal of Immunology*, vol. 186, no. 4, pp. 2672–2680, 2011.

[14] I. Wong-Baeza, A. Ridley, J. Shaw et al., "KIR3DL2 binds to HLA-B27 dimers and free chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis," *Journal of Immunology*, vol. 190, no. 7, pp. 3216–3224, 2013.

[15] T. M. Tran, N. Satumtira, M. L. Dorris et al., "HLA-B27 in transgenic rats forms disulfide-linked heavy chain oligomers and multimers that bind to the chaperone BiP," *Journal of Immunology*, vol. 172, no. 8, pp. 5110–5119, 2004.

[16] H. C. Yu, M. C. Lu, C. Li et al., "Targeted delivery of an antigenic peptide to the endoplasmic reticulum: application for development of a peptide therapy for ankylosing spondylitis," *PLoS One*, vol. 8, no. 10, article e77451, 2013.

[17] G. S. Hotamisligil, "Endoplasmic reticulum stress and the inflammatory basis of metabolic disease," *Cell*, vol. 140, no. 6, pp. 900–917, 2010.

[18] H. L. Pahl, "Signal transduction from the endoplasmic reticulum to the cell nucleus," *Physiological Reviews*, vol. 79, no. 3, pp. 683–701, 1999.

[19] M. J. Turner, D. P. Sowders, M. L. DeLay et al., "HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response," *Journal of Immunology*, vol. 175, no. 4, pp. 2438–2448, 2005.

[20] M. J. Turner, M. L. DeLay, S. Bai, E. Klenk, and R. A. Colbert, "HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlated with the magnitude of the unfolded protein response in transgenic rats," *Arthritis and Rheumatism*, vol. 56, no. 1, pp. 215–223, 2007.

[21] M. L. DeLay, M. J. Turner, E. I. Klenk, J. A. Smith, D. P. Sowders, and R. A. Colbert, "HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats," *Arthritis and Rheumatism*, vol. 60, no. 9, pp. 2633–2643, 2009.

[22] J. P. Mear, K. L. Schreiber, C. Münn et al., "Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies," *The Journal of Immunology*, vol. 163, no. 12, pp. 6665–6670, 1999.

[23] M. Sugita and M. B. Brenner, "An unstable beta 2-microglobulin: major histocompatibility complex class I heavy chain intermediate dissociates from calcxin and then is stabilized by binding peptide," *Journal of Experimental Medicine*, vol. 180, no. 6, pp. 2163–2171, 1994.

[24] M. Ramos, I. Alvarez, L. Sesma, A. Logean, D. Rognan, and J. A. López de Castro, "Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins," *Journal of Biological Chemistry*, vol. 277, no. 40, pp. 37573–37581, 2002.

[25] F. García, A. Marina, J. P. Albar, and J. A. López de Castro, "HLA-B27 presents a peptide from a polymorphic region of its own molecule with homology to proteins from arthro- genic bacteria," *Tissue Antigens*, vol. 49, no. 1, pp. 23–28, 1997.

[26] S. Ruben, A. Perkins, R. Purcell et al., "Structural and functional characterization of human immunodeficiency virus tat protein," *Journal of Virology*, vol. 63, no. 1, pp. 1–8, 1999.

[27] H. Brook, B. Lebleu, and E. Vives, "Tat peptide-mediated cellular delivery: back to basics," *Advanced Drug Delivery Reviews*, vol. 57, no. 4, pp. 559–577, 2005.

[28] M. J. Androlewicz, B. Ortmann, P. M. van Endert, T. Spies, and P. Cresswell, "Characteristics of peptide and major histocompatibility complex class I/beta 2-microglobulin binding to the transporters associated with antigen processing (TAP1 and TAP2)," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 26, pp. 12716–12720, 1994.

[29] U. Ritz and B. Seliger, "The transporter associated with antigen processing (TAP): structural integrity, expression, function,
and its clinical relevance,” *Molecular Medicine*, vol. 7, no. 3, pp. 149–158, 2001.

[30] S. Van der Linden, H. A. Valkenburg, and A. Cats, “Evaluation of diagnosis criteria for ankylosing spondylitis. A proposal for modification of the New York criteria,” *Arthritis and Rheumatism*, vol. 27, no. 4, pp. 361–368, 1984.

[31] M. C. Lu, N. S. Lai, H. C. Yu, S. C. Hsieh, C. H. Tung, and C. L. Yu, “Nifedipine suppresses Th1/Th2 cytokine production and increased apoptosis of anti-CD3 + anti-CD28-activated mononuclear cells from patients with systemic lupus erythematosus via calcineurin pathway,” *Clinical Immunology*, vol. 129, no. 3, pp. 462–470, 2008.

[32] J. Zemmour, A. M. Little, D. J. Schendel, and P. Parham, “The HLA-A,B “negative” mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon,” *Journal of Immunology*, vol. 148, no. 6, pp. 1941–1948, 1992.

[33] H. G. Rammensee, K. Falk, and O. Rötzschke, “Peptide naturally presented by MHC class I molecules,” *Annual Review of Immunology*, vol. 11, no. 1, pp. 213–244, 1993.

[34] H. C. Yu, K. Y. Huang, M. C. Lu et al., “Characterization of the recognition specificity of BH2, a monoclonal antibody prepared against the HLA-B27 heavy chain,” *International Journal of Molecular Sciences*, vol. 16, no. 4, pp. 8142–8150, 2015.

[35] C. J. Barnstable, W. F. Bodmer, G. Brown et al., “Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis,” *Cell*, vol. 14, no. 1, pp. 9–20, 1978.

[36] H. Shen, J. C. Goodall, and J. S. Hill Gaston, “Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis,” *Arthritis and Rheumatism*, vol. 60, no. 6, pp. 1647–1656, 2009.

[37] F. Ciccia, M. Bombardieri, A. Principato et al., “Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis,” *Arthritis and Rheumatism*, vol. 60, no. 4, pp. 955–965, 2009.

[38] L. Zeng, M. J. Lindstrom, and J. A. Smith, “Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response,” *Arthritis and Rheumatism*, vol. 63, no. 12, pp. 3807–3817, 2011.

[39] Y. Iwakura and H. Ishigame, “The IL-23/IL-17 axis in inflammation,” *Journal of Clinical Investigation*, vol. 116, no. 5, pp. 1218–1222, 2006.

[40] H. C. Yu, M. C. Lu, K. Y. Huang et al., “Sulfasalazine treatment suppresses the formation of HLA-B27 heavy chain homodimer in patients with ankylosing spondylitis,” *International Journal of Molecular Sciences*, vol. 17, no. 1, p. 46, 2016.

[41] S. K. Payeli, S. Kollnberger, O. Marroquin Belaunzaran et al., “Inhibiting HLA-B27 homodimer–driven immune cell inflammation in spondylarthritids,” *Arthritis and Rheumatism*, vol. 64, no. 10, pp. 3139–3149, 2012.

[42] J. Sieper, “Developments in therapies for spondyloarthritis,” *Nature Reviews. Rheumatology*, vol. 8, no. 5, pp. 280–287, 2012.

[43] J. Keane, S. Gershon, R. P. Wise et al., “Tuberculosis associated with infliximab, a tumor necrosis factor α–neutralizing agent,” *New England Journal of Medicine*, vol. 345, no. 15, pp. 1098–1104, 2001.

[44] F. M. Milanez, C. G. S. Saad, V. T. Viana et al., “IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis,” *Arthritis Research & Therapy*, vol. 18, no. 1, p. 52, 2016.

[45] H. Jethwa and P. Bowness, “The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment,” *Clinical and Experimental Immunology*, vol. 183, no. 1, pp. 30–36, 2015.

[46] D. Baeten, X. Baraliakos, J. Braun et al., “Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial,” *Lancet*, vol. 382, no. 9906, pp. 1705–1713, 2013.